is predicted to increase the exposure to aliskiren.
▶ Macrolides (clarithromycin, erythromycin) are predicted to
increase the exposure to aliskiren.oStudy
▶ Clarithromycin increases the exposure to almotriptan.n
▶ Clarithromycin is predicted to moderately increase the
exposure to alpha blockers (alfuzosin, tamsulosin). Use with
▶ Clarithromycin is predicted to increase the exposure to alpha
▶ Erythromycin is predicted to increase the exposure to alpha
blockers (tamsulosin).oTheoretical
▶ Clarithromycin moderately increases the exposure to
▶ Erythromycin is predicted to increase the exposure to
▶ Azithromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
aminophylline. Adjust dose.oTheoretical
▶ Aminophylline is predicted to decrease the exposure to
erythromycin. Adjust dose.rStudy
▶ Clarithromycin very markedly increases the exposure to
antiarrhythmics (dronedarone). Avoid.rStudy → Also see
▶ Erythromycin is predicted to moderately increase the exposure
to antiarrhythmics (dronedarone). Avoid.rTheoretical →
▶ Macrolides (clarithromycin, erythromycin) are predicted to
antiarrhythmics (lidocaine).o ▶ Clarithromycin is predicted to increase the exposure to
(propafenone). Monitor and adjust dose.r
▶ Erythromycin is predicted to increase the exposure to
(propafenone). Monitor and adjust dose.
▶ Clarithromycin is predicted to increase the exposure to
anticholinesterases, centrally acting (galantamine). Monitor and
▶ Clarithromycin slightly increases the concentration of
antiepileptics (carbamazepine). Monitor concentration and
▶ Erythromycin markedly increases the concentration of
antiepileptics (carbamazepine). Monitor concentration and
▶ Clarithromycin is predicted to very slightly increase the
exposure to antiepileptics (perampanel).nStudy
▶ Clarithromycin is predicted to increase the exposure to
antifungals, azoles (isavuconazole). Avoid or monitor side
▶ Erythromycin is predicted to increase the exposure to
antifungals, azoles (isavuconazole).oTheoretical
▶ Clarithromycin is predicted to increase the exposure to
antihistamines, non-sedating (mizolastine). Avoid.rStudy
▶ Erythromycin is predicted to increase the exposure to
antihistamines, non-sedating (mizolastine).rTheoretical
▶ Macrolides (clarithromycin, erythromycin) are predicted to
increase the exposure to antihistamines, non-sedating
▶ Macrolides (clarithromycin, erythromycin) are predicted to
▶ Clarithromycin is predicted to increase the exposure to
apalutamide.nStudy → Also see TABLE 9 p. 1377
▶ Erythromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to markedly increase the exposure
▶ Erythromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to slightly increase the exposure to
aripiprazole. Adjust aripiprazole dose, p. 395.oStudy
▶ Clarithromycin is predicted to increase the exposure to
axitinib. Avoid or adjust dose.oStudy
is predicted to increase the exposure to axitinib.
▶ Clarithromycin is predicted to increase the exposure to
bedaquiline. Avoid prolonged use.nStudy → Also see TABLE 9
▶ Erythromycin is predicted to increase the exposure to
bedaquiline. Avoid prolonged use.nTheoretical → Also see
▶ Macrolides are predicted to increase the exposure to beta
blockers, non-selective (nadolol).oStudy
▶ Clarithromycin is predicted to increase the exposure to beta2
agonists (salmeterol). Avoid.rStudy
▶ Macrolides are predicted to increase the exposure to
bictegravir. Use with caution or avoid.oTheoretical
slightly increases the exposure to bortezomib.
▶ Clarithromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to markedly increase the exposure
to bosutinib. Avoid or adjust dose.rStudy → Also see
▶ Erythromycin is predicted to increase the exposure to
bosutinib. Avoid or adjust dose.rTheoretical → Also see
▶ Clarithromycin is predicted to increase the exposure to
brigatinib. Adjust brigatinib dose, p. 971.rStudy
▶ Clarithromycin is predicted to increase the exposure to
buspirone. Adjust buspirone dose, p. 342.rStudy
▶ Erythromycin is predicted to increase the exposure to
buspirone. Use with caution and adjust dose.oStudy
slightly increases the exposure to cabozantinib.
Study → Also see TABLE 9 p. 1377
▶ Erythromycin is predicted to increase the exposure to
cabozantinib.oTheoretical → Also see TABLE 9 p. 1377
▶ Erythromycin is predicted to increase the exposure to calcium
channel blockers (amlodipine, felodipine, lacidipine,
lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
▶ Clarithromycin is predicted to increase the exposure to calcium
channel blockers (amlodipine, felodipine, lacidipine, nicardipine,
. Monitor and adjust dose.o ▶ Erythromycin is predicted to increase the exposure to calcium
channel blockers (diltiazem).rTheoretical
▶ Clarithromycin is predicted to increase the exposure to calcium
channel blockers (diltiazem, verapamil).rStudy
▶ Clarithromycin is predicted to markedly increase the exposure
to calcium channel blockers (lercanidipine). Avoid.rStudy
1484 Macitentan — Macrolides BNF 78
▶ Erythromycin is predicted to increase the exposure to calcium
channel blockers (verapamil).rStudy
▶ Clarithromycin is predicted to increase the exposure to
. Use with caution and adjust dose.o ▶ Clarithromycin is predicted to moderately increase the
exposure to cariprazine. Avoid.rStudy
▶ Erythromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
ceritinib. Avoid or adjust ceritinib dose, p. 973.rStudy →
▶ Macrolides (azithromycin, erythromycin) are predicted to
increase the exposure to ceritinib.oTheoretical → Also
increases the concentration of ciclosporin.
▶ Erythromycin is predicted to increase the concentration of
▶ Clarithromycin is predicted to moderately increase the
Adjust cilostazol dose, p. 232.oStudy
▶ Clarithromycin is predicted to moderately increase the
exposure to cinacalcet. Adjust dose.oStudy
▶ Erythromycin potentially increases the risk of toxicity when
given with clozapine.rAnecdotal
▶ Clarithromycin is predicted to markedly increase the exposure
to cobimetinib. Avoid or monitor for toxicity.rStudy
▶ Erythromycin is predicted to increase the exposure to
▶ Azithromycin is predicted to increase the exposure to
. Avoid or adjust colchicine dose, p. 1120.r
▶ Clarithromycin is predicted to increase the exposure to
colchicine. Avoid potent inhibitors of CYP3A4 or adjust
colchicine dose, p. 1120.rStudy
▶ Erythromycin is predicted to increase the exposure to
colchicine. Adjust colchicine dose with moderate inhibitors of
▶ Clarithromycin is predicted to increase the exposure to
corticosteroids (beclometasone) (risk with beclometasone is
corticosteroids (betamethasone, budesonide, ciclesonide,
deflazacort, dexamethasone, fludrocortisone, fluticasone,
hydrocortisone, methylprednisolone, mometasone,
. Avoid or monitor side effects.
▶ Erythromycin is predicted to increase the exposure to
(methylprednisolone). Monitor and adjust dose.
▶ Macrolides (clarithromycin, erythromycin) increase the
anticoagulant effect of coumarins. Monitor INR and adjust
▶ Clarithromycin is predicted to moderately increase the
exposure to crizotinib. Avoid.oStudy → Also see TABLE 9
▶ Macrolides are predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
dabrafenib. Use with caution or avoid.oStudy
▶ Clarithromycin is predicted to markedly to very markedly
increase the exposure to darifenacin. Avoid.rStudy
▶ Erythromycin is predicted to slightly increase the exposure to
▶ Clarithromycin is predicted to markedly increase the exposure
dasatinib. Avoid or adjust dose—consult product literature.
Study → Also see TABLE 9 p. 1377
▶ Erythromycin is predicted to increase the exposure to
dasatinib.rStudy → Also see TABLE 9 p. 1377
▶ Clarithromycin very slightly increases the exposure to
delamanid.rStudy → Also see TABLE 9 p. 1377
increase the concentration of digoxin.r
▶ Macrolides (clarithromycin, erythromycin) increase the risk of
QT-prolongation when given with
▶ Clarithromycin increases the exposure to dopamine receptor
agonists (bromocriptine).rStudy
▶ Erythromycin is predicted to increase the exposure to
dopamine receptor agonists (bromocriptine).rTheoretical
▶ Macrolides (clarithromycin, erythromycin) are predicted to
increase the concentration of dopamine receptor agonists
▶ Clarithromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
▶ Erythromycin slightly increases the exposure to edoxaban.
Adjust edoxaban dose, p. 126.rStudy
▶ Macrolides (azithromycin, clarithromycin) are predicted to
slightly increase the exposure to edoxaban.rTheoretical
clarithromycin.o ▶ Clarithromycin is predicted to markedly increase the exposure
▶ Erythromycin moderately increases the exposure to eletriptan.
▶ Macrolides (clarithromycin, erythromycin) are predicted to
increase the exposure to eliglustat. Avoid or adjust dose—
consult product literature.rStudy
▶ Clarithromycin is predicted to increase the exposure to
encorafenib. Avoid or monitor.rStudy → Also see TABLE 9
▶ Erythromycin is predicted to moderately increase the exposure
to encorafenib.oStudy → Also see TABLE 9 p. 1377
▶ Clarithromycin is predicted to increase the risk of ergotism
when given with ergometrine. Avoid.rTheoretical
▶ Erythromycin is predicted to increase the risk of ergotism
when given with ergometrine.rTheoretical
▶ Clarithromycin is predicted to increase the risk of ergotism
when given with ergotamine. Avoid.rTheoretical
▶ Erythromycin is predicted to increase the risk of ergotism
when given with ergotamine.rTheoretical
▶ Clarithromycin is predicted to slightly increase the exposure to
erlotinib. Use with caution and adjust dose.oStudy
▶ Macrolides (azithromycin, erythromycin) are predicted to
increase the exposure to erlotinib.oTheoretical
▶ Clarithromycin is predicted to increase the exposure to
esketamine. Adjust dose.oStudy
▶ Etravirine decreases the exposure to clarithromycin and
slightly increases the exposure to etravirine.
▶ Clarithromycin is predicted to increase the concentration of
▶ Erythromycin is predicted to increase the concentration of
everolimus. Avoid or adjust dose.oStudy
▶ Clarithromycin is predicted to moderately increase the
exposure to fesoterodine. Adjust fesoterodine dose with potent
inhibitors of CYP3A4; avoid in hepatic and renal impairment,
▶ Erythromycin is predicted to increase the exposure to
fesoterodine. Adjust fesoterodine dose with moderate
inhibitors of CYP3A4 in hepatic and renal impairment, p. 777.
▶ Macrolides are predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
is predicted to increase the exposure to gefitinib.
BNF 78 Macrolides — Macrolides 1485
▶ Clarithromycin is predicted to moderately to markedly increase
the exposure to grazoprevir. Avoid.rStudy
▶ Clarithromycin is predicted to increase the exposure to
guanfacine. Adjust guanfacine dose, p. 352.oStudy
▶ Erythromycin is predicted to increase the concentration of
guanfacine. Adjust guanfacine dose, p. 352.oTheoretical
▶ H2 receptor antagonists (cimetidine) slightly increase the
exposure to erythromycin.oStudy
▶ HIV-protease inhibitors (atazanavir) are predicted to increase the
clarithromycin. Adjust dose in renal impairment.
▶ HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir,
lopinavir, ritonavir, tipranavir) are predicted to increase the
exposure to erythromycin.rTheoretical
▶ HIV-protease inhibitors (darunavir, fosamprenavir, lopinavir)
(boosted with ritonavir) are predicted to increase the
clarithromycin. Adjust dose in renal impairment.
▶ HIV-protease inhibitors (ritonavir) increase the exposure to
clarithromycin. Adjust dose in renal impairment.rStudy
▶ HIV-protease inhibitors (tipranavir boosted with ritonavir)
increase the exposure to clarithromycin and clarithromycin
increases the exposure to HIV-protease inhibitors (tipranavir)
(boosted with ritonavir). Monitor; adjust dose in renal
▶ Clarithromycin increases the exposure to HIV-protease inhibitors
(saquinavir) and HIV-protease inhibitors (saquinavir) increase
the exposure to clarithromycin. Avoid.rStudy → Also see
▶ Clarithromycin is predicted to very markedly increase the
exposure to ibrutinib. Avoid potent inhibitors of CYP3A4 or
adjust ibrutinib dose, p. 983.rStudy
▶ Erythromycin is predicted to increase the exposure to
ibrutinib. Adjust ibrutinib dose with moderate inhibitors of
▶ Clarithromycin is predicted to increase the exposure to
is predicted to increase the exposure to imatinib.
▶ Clarithromycin is predicted to increase the risk of toxicity
when given with irinotecan. Avoid.oStudy
▶ Clarithromycin is predicted to increase the exposure to
▶ Erythromycin is predicted to increase the exposure to
ivabradine. Avoid.rTheoretical
▶ Clarithromycin is predicted to increase the exposure to
ivacaftor. Adjust ivacaftor p. 293 or lumacaftor with ivacaftor
p. 294 or tezacaftor with ivacaftor p. 295 dose with potent
▶ Erythromycin is predicted to increase the exposure to
ivacaftor. Adjust ivacaftor p. 293 or tezacaftor with ivacaftor
p. 295 dose with moderate inhibitors of CYP3A4.rStudy
▶ Clarithromycin is predicted to increase the exposure to
lapatinib. Avoid.oStudy → Also see TABLE 9 p. 1377
▶ Erythromycin is predicted to increase the exposure to
lapatinib.oStudy → Also see TABLE 9 p. 1377
▶ Macrolides (clarithromycin, erythromycin) are predicted to
increase the concentration of letermovir.oStudy
increases the exposure to linezolid.o ▶ Azithromycin is predicted to increase the exposure to
▶ Erythromycin is predicted to increase the exposure to
lomitapide. Avoid.oTheoretical
▶ Lumacaftor is predicted to decrease the exposure to macrolides
(clarithromycin, erythromycin).oTheoretical
▶ Clarithromycin is predicted to increase the exposure to
▶ Erythromycin is predicted to increase the exposure to
lurasidone. Adjust lurasidone dose, p. 398.oStudy
▶ Clarithromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to markedly increase the exposure
to maraviroc. Adjust dose.rStudy
▶ Clarithromycin is predicted to markedly to very markedly
midazolam. Avoid or adjust dose.
▶ Erythromycin is predicted to increase the exposure to
midazolam. Monitor side effects and adjust dose.rStudy
▶ Clarithromycin is predicted to very markedly increase the
midostaurin. Avoid or monitor for toxicity.r
▶ Erythromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
mirabegron. Adjust mirabegron dose in hepatic and renal
▶ Clarithromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
▶ Clarithromycin increases the risk of neutropenia when given
with monoclonal antibodies (brentuximab vedotin). Monitor and
▶ Clarithromycin is predicted to increase the exposure to
(trastuzumab emtansine). Avoid.r
▶ Clarithromycin is predicted to markedly increase the exposure
▶ Erythromycin is predicted to increase the exposure to
. Adjust naloxegol dose and monitor side effects, p. 65.
▶ Clarithromycin is predicted to increase the exposure to
decreases the exposure to clarithromycin.o ▶ Clarithromycin is predicted to moderately increase the
exposure to nilotinib. Avoid.rStudy → Also see TABLE 9
is predicted to increase the exposure to nilotinib.
Theoretical → Also see TABLE 9 p. 1377
▶ Macrolides are predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
nitisinone. Adjust dose.oTheoretical
▶ Clarithromycin is predicted to increase the exposure to
olaparib. Avoid potent inhibitors of CYP3A4 or adjust olaparib
▶ Erythromycin is predicted to increase the exposure to olaparib.
Avoid moderate inhibitors of CYP3A4 or adjust olaparib dose,
▶ Erythromycin is predicted to increase the exposure to opioids
(alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and
▶ Clarithromycin is predicted to increase the exposure to opioids
(alfentanil, buprenorphine, fentanyl, oxycodone, sufentanil).
Monitor and adjust dose.rStudy
▶ Clarithromycin is predicted to increase the concentration of
opioids (methadone).rTheoretical → Also see TABLE 9 p. 1377
▶ Erythromycin is predicted to increase the exposure to opioids
(methadone, sufentanil).oTheoretical → Also see TABLE 9
▶ Clarithromycin is predicted to increase the exposure to
. Avoid in poor CYP2C9 metabolisers.o ▶ Clarithromycin is predicted to increase the exposure to
▶ Erythromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
palbociclib. Avoid or adjust palbociclib dose, p. 992.rStudy
▶ Clarithromycin is predicted to increase the exposure to
panobinostat. Adjust panobinostat dose; in hepatic
1486 Macrolides — Macrolides BNF 78
impairment avoid, p. 936.oStudy → Also see TABLE 9
▶ Macrolides (azithromycin, erythromycin) are predicted to
Theoretical → Also see TABLE 9
. Adjust dose.o ▶ Clarithromycin is predicted to increase the exposure to
▶ Erythromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
pazopanib dose, p. 993.o ▶ Erythromycin is predicted to increase the exposure to
pazopanib.oTheoretical → Also see TABLE 9 p. 1377
▶ Erythromycin is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (avanafil). Adjust avanafil
▶ Clarithromycin is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors
(avanafil, vardenafil). Avoid.
Study → Also see TABLE 9 p. 1377
▶ Clarithromycin is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (sildenafil). Avoid potent
inhibitors of CYP3A4 or adjust
Study → Also see TABLE 9 p. 1377
▶ Erythromycin is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (sildenafil). Monitor or
adjust sildenafil dose with moderate inhibitors of CYP3A4,
p. 813.oStudy → Also see TABLE 9 p. 1377
▶ Clarithromycin is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (tadalafil). Use with caution
▶ Erythromycin is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (tadalafil).rTheoretical
▶ Erythromycin is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors
Theoretical → Also see TABLE 9 p. 1377
▶ Macrolides are predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
pimozide. Avoid.rStudy → Also see TABLE 9 p. 1377
▶ Erythromycin is predicted to increase the exposure to
pimozide. Avoid.rTheoretical → Also see TABLE 9 p. 1377
▶ Clarithromycin is predicted to slightly increase the exposure to
exposure to praziquantel.nStudy
▶ Clarithromycin is predicted to increase the exposure to
▶ Erythromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
ranolazine. Avoid.rStudy → Also see TABLE 9 p. 1377
▶ Erythromycin is predicted to increase the exposure to
ranolazine.rStudy → Also see TABLE 9 p. 1377
▶ Clarithromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
ribociclib dose, p. 997.o ▶ Erythromycin is predicted to increase the exposure to
ribociclib.oStudy → Also see TABLE 9 p. 1377
▶ Azithromycin increases the risk of neutropenia when given
▶ Clarithromycin increases the risk of uveitis when given with
▶ Erythromycin is predicted to increase the risk of uveitis when
given with rifabutin. Adjust dose.rTheoretical
decreases the concentration of clarithromycin.
▶ Clarithromycin is predicted to increase the exposure to
risperidone. Adjust dose.oStudy → Also see TABLE 9
▶ Clarithromycin is predicted to increase the exposure to
. Adjust dose and monitor side effects.o ▶ Erythromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
▶ Erythromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the concentration of
▶ Erythromycin increases the concentration of sirolimus.
Monitor and adjust dose.oStudy
▶ Clarithromycin is predicted to increase the exposure to
solifenacin. Adjust solifenacin p. 779 or tamsulosin with
p. 786 dose; avoid in hepatic and renal impairment.
▶ Clarithromycin is predicted to moderately increase the
exposure to SSRIs (dapoxetine). Avoid potent inhibitors of
CYP3A4 or adjust dapoxetine dose, p. 821.rStudy
▶ Erythromycin is predicted to increase the exposure to SSRIs
(dapoxetine). Adjust dapoxetine dose with moderate inhibitors
of CYP3A4, p. 821.oTheoretical
▶ Clarithromycin is predicted to increase the exposure to statins
(atorvastatin). Avoid or adjust dose and monitor
▶ Erythromycin is predicted to increase the exposure to statins
(atorvastatin). Monitor and adjust dose.rStudy
▶ Clarithromycin moderately increases the exposure to statins
▶ Erythromycin is predicted to increase the exposure to statins
▶ Clarithromycin is predicted to increase the exposure to statins
▶ Erythromycin is predicted to increase the exposure to statins
(simvastatin). Use with caution and adjust simvastatin dose,
▶ Clarithromycin is predicted to slightly increase the exposure to
▶ Clarithromycin is predicted to slightly increase the exposure to
sunitinib dose, p. 999.o ▶ Erythromycin is predicted to increase the exposure to
sunitinib.oTheoretical → Also see TABLE 9 p. 1377
▶ Clarithromycin is predicted to increase the concentration of
tacrolimus. Monitor and adjust dose.rStudy
▶ Erythromycin is predicted to increase the concentration of
▶ Clarithromycin is predicted to increase the exposure to taxanes
▶ Erythromycin is predicted to increase the exposure to taxanes
▶ Clarithromycin is predicted to moderately increase the
taxanes (docetaxel). Avoid or adjust dose.r
▶ Clarithromycin is predicted to increase the exposure to taxanes
▶ Clarithromycin is predicted to increase the concentration of
temsirolimus. Avoid.rTheoretical
▶ Erythromycin is predicted to increase the concentration of
▶ Clarithromycin is predicted to increase the exposure to
tezacaftor. Adjust tezacaftor with ivacaftor p. 295 dose with
potent inhibitors of CYP3A4.rStudy
▶ Erythromycin is predicted to increase the exposure to
tezacaftor. Adjust tezacaftor with ivacaftor p. 295 dose with
moderate inhibitors of CYP3A4.rStudy
▶ Erythromycin decreases the clearance of theophylline and
theophylline potentially decreases the clearance of
erythromycin. Adjust dose.rStudy
BNF 78 Macrolides — Macrolides 1487
▶ Macrolides (azithromycin, clarithromycin) are predicted to
theophylline. Adjust dose.o ▶ Azithromycin is predicted to increase the exposure to
ticagrelor. Use with caution or avoid.rStudy
▶ Clarithromycin is predicted to markedly increase the exposure
▶ Clarithromycin is predicted to increase the exposure to
tofacitinib. Adjust tofacitinib dose, p. 1105.oStudy
▶ Erythromycin given with a potent CYP2C19 inhibitor is
predicted to increase the exposure to tofacitinib. Adjust
tofacitinib dose, p. 1105.oStudy
▶ Clarithromycin is predicted to increase the exposure to
tolterodine. Avoid.rStudy → Also see TABLE 9 p. 1377
▶ Erythromycin is predicted to increase the exposure to
tolterodine.nTheoretical → Also see TABLE 9 p. 1377
▶ Clarithromycin is predicted to increase the exposure to
tolvaptan. Manufacturer advises caution or adjust tolvaptan
dose with potent inhibitors of CYP3A4, p. 669.rStudy
▶ Erythromycin is predicted to increase the exposure to
tolvaptan. Manufacturer advises caution or adjust tolvaptan
dose with moderate inhibitors of CYP3A4,
p. 669.o ▶ Macrolides are predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
toremifene.oTheoretical → Also see TABLE 9 p. 1377
▶ Clarithromycin is predicted to increase the exposure to
trabectedin. Avoid or adjust dose.rTheoretical
▶ Macrolides are predicted to increase the concentration of
▶ Clarithromycin is predicted to moderately increase the
exposure to trazodone. Avoid or adjust dose.oStudy
▶ Erythromycin is predicted to increase the exposure to
▶ Clarithromycin is predicted to increase the exposure to
ulipristal. Avoid if used for uterine fibroids.rStudy
▶ Erythromycin is predicted to increase the exposure to
ulipristal. Avoid if used for uterine fibroids.oStudy
▶ Clarithromycin is predicted to increase the exposure to
vemurafenib.rTheoretical → Also see TABLE 9 p. 1377
▶ Macrolides (clarithromycin, erythromycin) are predicted to
increase the exposure to venetoclax. Avoid or adjust dose—
consult product literature.rStudy
▶ Clarithromycin is predicted to increase the exposure to
venlafaxine.oStudy → Also see TABLE 9 p. 1377
▶ Macrolides (clarithromycin, erythromycin) are predicted to
increase the exposure to vinca alkaloids.rTheoretical →
▶ Clarithromycin is predicted to increase the exposure to vitamin
D substances (paricalcitol).oStudy
▶ Clarithromycin decreases the absorption of zidovudine.
Separate administration by at least 2 hours.oStudy
▶ Clarithromycin is predicted to increase the exposure to
zopiclone. Adjust dose.oTheoretical
▶ Erythromycin is predicted to increase the exposure to
▶ Oral magnesium decreases the absorption of bisphosphonates
(alendronic acid). Alendronic acid should be taken at least
30 minutes before magnesium.oStudy
▶ Oral magnesium is predicted to decrease the absorption of oral
bisphosphonates (ibandronic acid). Avoid magnesium for at least
6 hours before or 1 hour after
ibandronic acid.o ▶ Oral magnesium decreases the absorption of bisphosphonates
No comments:
Post a Comment
اكتب تعليق حول الموضوع